Participant flow

A Study of Selpercatinib (LY3527723) in Participants With RET-Mutant Medullary Thyroid Cancer · Source last updated 2026-03-19

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

groups

1. description

   160 milligrams (mg) Selpercatinib administered orally (PO) twice daily (BID). Adolescent Dose: 92 milligrams per square meter (mg/m2) BID (not to exceed 160 mg BID).

   id

   FG000

   title

   Selpercatinib - Treatment A (TRT A)

2. description

   140 mg Cabozantinib administered orally daily (QD) or 300 mg Vandetanib administered orally QD per physician choice. Cabozantinib Adolescent Dose: 40 mg/m2. Vandetanib Adolescent Dose: * 0.7 - \<0.9 - 100 mg every other day (QOD) * 0.9 - \<1.2 - 100 mg QD * 1.2 - \<1.6 - 7-day schedule 100 mg - 200 mg - 100 mg - 200 mg - 100 mg - 200 mg - 100 mg * ≥1.6 - 200 QD

   id

   FG001

   title

   Cabozantinib or Vandetanib - Treatment B (TRT B)

periods

1. drop Withdraws

   1. reasons

      1. group Id

         FG000

         num Subjects

         175

      2. group Id

         FG001

         num Subjects

         40

      type

      On Treatment

   2. reasons

      1. group Id

         FG000

         num Subjects

         0

      2. group Id

         FG001

         num Subjects

         2

      type

      Withdrawal by Subject

   milestones

   1. achievements

      1. group Id

         FG000

         num Subjects

         193

      2. group Id

         FG001

         num Subjects

         98

      type

      STARTED

   2. achievements

      1. group Id

         FG000

         num Subjects

         193

      2. group Id

         FG001

         num Subjects

         97

      type

      Received at Least One Dose of Study Drug

   3. achievements

      1. group Id

         FG000

         num Subjects

         18

      2. group Id

         FG001

         num Subjects

         56

      type

      COMPLETED

   4. achievements

      1. group Id

         FG000

         num Subjects

         175

      2. group Id

         FG001

         num Subjects

         42

      type

      NOT COMPLETED

   title

   Overall Study

pre Assignment Details

If a participant has a recorded death on study, or is alive and being followed but off treatment, then the participant can be considered to be study completer. Participants randomized to the Cabozantinib or Vandetanib arm will be allowed to crossover to receive the investigational product at the time of Blinded Independent Committee Review (BICR) confirmed radiographic progression.

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice